Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer

BACKGROUND: Gemcitabine (Gem) has limited clinical benefits in pancreatic ductal adenocarcinoma (PDAC). Sunitinib (Su) is a novel, multi-target receptor tyrosine kinase inhibitor that has antitumour activities. This study tested the benefits of combined gemcitabine and sunitinib in PDAC. METHODS: Ce...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Awasthi, Niranjan, Schwarz, Margaret A, Schwarz, Roderich E
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Publishing Ltd 2011
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3183443/
https://ncbi.nlm.nih.gov/pubmed/21843259
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1477-2574.2011.00333.x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars